Benzinga | Sep 17, 2020 08:02AM EDT

Document Security Systems Announces Its Impact BioMedical Subsidiary Completed Efficacy Testing Of Its Proprietary 3F Antiviral Biofragrance

ROCHESTER, N.Y., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Document Security Systems, Inc. ("DSS" or the "Company") (NYSE:DSS), a multinational company operating businesses focusing on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets, today announced its wholly owned subsidiary Impact BioMedical, Inc. ("Impact BioMedical"), through its subsidiary Global BioLife, Inc. ("Global BioLife"), completed efficacy testing of its proprietary 3F Antiviral Biofragrance ("3F Biofragrance) at a biosafety level 3 containment facility at an independent university. The study demonstrated a 10-fold reduction in COVID-19 viral population on surfaces using 3F Biofragrance.